Northwest Bioth Cmn (NWBO): Price and Financial Metrics

NWBO POWR Grades

• Sentiment is the dimension where NWBO ranks best; there it ranks ahead of 52.57% of US stocks.
• The strongest trend for NWBO is in Quality, which has been heading up over the past 177 days.
• NWBO's current lowest rank is in the Growth metric (where it is better than 1.57% of US stocks).

NWBO Stock Summary

• With a price/sales ratio of 707.72, NORTHWEST BIOTHERAPEUTICS INC has a higher such ratio than 99.31% of stocks in our set.
• NWBO's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 5.9% of US stocks.
• Revenue growth over the past 12 months for NORTHWEST BIOTHERAPEUTICS INC comes in at -27.98%, a number that bests just 6.64% of the US stocks we're tracking.
• If you're looking for stocks that are quantitatively similar to NORTHWEST BIOTHERAPEUTICS INC, a group of peers worth examining would be WATT, SDGR, MNTS, CLXT, and ENTX.
• Visit NWBO's SEC page to see the company's official filings. To visit the company's web site, go to www.nwbio.com.

NWBO Valuation Summary

• In comparison to the median Healthcare stock, NWBO's EV/EBIT ratio is 26.26% higher, now standing at 12.5.
• NWBO's EV/EBIT ratio has moved up 12.3 over the prior 243 months.

Below are key valuation metrics over time for NWBO.

NWBO Growth Metrics

Its year over year cash and equivalents growth rate is now at -6.76%.
• Its 4 year revenue growth rate is now at 480.44%.
• Its 4 year net income to common stockholders growth rate is now at 103.65%.

NWBO's revenue has moved down $1,324,000 over the prior 33 months.

The table below shows NWBO's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2022-09-30	1.086	-55.172	56.586
2022-06-30	1.23	-46.067	134.957
2022-03-31	1.169	-38.018	169.035
2021-12-31	1.005	-38.299	179.126
2021-09-30	1.508	-37.256	-234.493
2021-06-30	1.374	-38.265	-474.108

NWBO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• NWBO has a Quality Grade of C, ranking ahead of 27.35% of graded US stocks.
• NWBO's asset turnover comes in at 0.045 -- ranking 328th of 682 Pharmaceutical Products stocks.
• EDSA, BLCM, and GLYC are the stocks whose asset turnover ratios are most correlated with NWBO.

The table below shows NWBO's key quality metrics over time.